Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Fischer, A. en_US
dc.contributor.author Karasi, J. C. en_US
dc.contributor.author Kibibi, D. en_US
dc.contributor.author Omes, C. en_US
dc.contributor.author Lambert, C. en_US
dc.contributor.author Uwayitu, A. en_US
dc.contributor.author Hemmer, R. en_US
dc.contributor.author Van den Ende, J. en_US
dc.contributor.author Schmit, J. C. en_US
dc.contributor.author Arendt, V. en_US
dc.date.accessioned 2007-12-06T14:38:38Z
dc.date.available 2007-12-06T14:38:38Z
dc.date.issued 2006 en_US
dc.identifier.doi http://dx.doi.org/10.1111/j.1468-1293.2005.00338.x
dc.identifier.other ITG-C8A en_US
dc.identifier.other CLINIC en_US
dc.identifier.other U-TROPIC en_US
dc.identifier.other JIF en_US
dc.identifier.other ABSTRACT en_US
dc.identifier.uri http://hdl.handle.net/10390/884
dc.description The definitive version is available at www3.interscience.wiley.com en_US
dc.description.abstract Our study aimed to complete the published data on ARV therapy in Africa by describing the baseline situation in Rwanda before the launch of a large ARV programme (ESTHER). Prescription habits, frequency and reasons for treatment interruptions but also antiviral efficay, resistance to ARVs and genotypic variability of the viruses present in Rwanda were analysed. Among the 233 patients included in the study, it appeared that a vast majority (91%) were under triple therapy and that half of them had experienced at least one treatment interruption caused mainly by drug shortage or financial difficulties. Among 60 blood samples analysed, 26 were in virological failure with a viral load above 1000 RNA copies/ml and 11 presented major drug resistance mutations. Finally, virological failure could mainly be explained by the high frequency of treatment interruptions but also by the emergence of drug resistance mutations. Consequently the major objective for the ESTHER programme to improve the situation in Rwanda will be to reduce the drug shortage and facilitate the financial accessibility of the treatments. en_US
dc.language English en_US
dc.publisher Blackwell Publishing en_US
dc.subject Viral diseases en_US
dc.subject HIV en_US
dc.subject AIDS en_US
dc.subject Antiretrovirals en_US
dc.subject Treatment outcome en_US
dc.subject Genotypes en_US
dc.subject Compliance en_US
dc.subject Drug availability en_US
dc.subject Affordability en_US
dc.subject Drug resistance en_US
dc.subject Mutations en_US
dc.subject Rwanda en_US
dc.subject Africa, Central en_US
dc.title Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002 en_US
dc.type Article en_US
dc.citation.issue 1 en_US
dc.citation.jtitle HIV Medicine en_US
dc.citation.volume 7 en_US
dc.citation.pages 64-66 en_US
dc.publisher.place Oxford en_US
dc.identifier.pmid http://www.ncbi.nlm.nih.gov/pubmed/16313295
dc.citation.jabbreviation HIV Med en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record